OpenNashEarnings

Biotechnology · Nasdaq: REGN

Regeneron earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 29 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Regeneron expanded its Sanofi alliance to add four Regeneron-invented, long-acting next-generation immunology antibodies meant to build on Dupixent, backed by a $1.0 billion up-front payment.

Regeneron's three core brands, Dupixent, EYLEA HD and Libtayo, each posted record quarterly sales on broad demand. EYLEA HD gained ground as retinal specialists adopted it after label enhancements, while older EYLEA lost volume to competition and the switch to EYLEA HD. Libtayo grew on an adjuvant skin cancer approval, and a shorter-interval dosing schedule won a positive European opinion. The FDA approved Pasatru for FOP, and a U.S. government agreement will supply Inmazeb for Ebola preparedness.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$5.1B+36.3% y/yQ3 2026
Q4 2024: $3.8B (worked out from the annual figure)Q4 ’24$3.8BQ1 2025: $3.0BQ1 ’25$3.0BQ2 2025: $3.7BQ2 ’25$3.7BQ3 2025: $3.8BQ3 ’25$3.8BQ4 2025: $3.9B (worked out from the annual figure)Q4 ’25$3.9BQ1 2026: $3.6BQ1 ’26$3.6BQ2 2026: $4.3BQ2 ’26$4.3BQ3 2026: $5.1BQ3 ’26$5.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$3.8B *
Q1 2025$3.0B
Q2 2025$3.7B
Q3 2025$3.8B
Q4 2025$3.9B *
Q1 2026$3.6B
Q2 2026$4.3B
Q3 2026$5.1B
Diluted EPS (GAAP)$18.45+35.5% y/yQ3 2026
Q1 2025: $7.27Q1 ’25$7.27Q2 2025: $12.81Q2 ’25$12.81Q3 2025: $13.62Q3 ’25$13.62Q1 2026: $6.75Q1 ’26$6.75Q2 2026: $12.23Q2 ’26$12.23Q3 2026: $18.45Q3 ’26$18.45
Data
Q1 2025$7.27
Q2 2025$12.81
Q3 2025$13.62
Q1 2026$6.75
Q2 2026$12.23
Q3 2026$18.45

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin40.0%+12.7 pts y/yQ3 2026
Q4 2024: 26.1%Q4 ’2426.1%Q1 2025: 19.5%Q1 ’2519.5%Q2 2025: 29.4%Q2 ’2529.4%Q3 2025: 27.3%Q3 ’2527.3%Q4 2025: 22.7%Q4 ’2522.7%Q1 2026: 17.8%Q1 ’2617.8%Q2 2026: 30.1%Q2 ’2630.1%Q3 2026: 40.0%Q3 ’2640.0%
Data
Q4 202426.1%
Q1 202519.5%
Q2 202529.4%
Q3 202527.3%
Q4 202522.7%
Q1 202617.8%
Q2 202630.1%
Q3 202640.0%
Free cash flow$1.5B+4.6% y/yQ3 2026
Q4 2024: $1.1BQ4 ’24$1.1BQ1 2025: $815.8MQ1 ’25$815.8MQ2 2025: $925.4MQ2 ’25$925.4MQ3 2025: $1.4BQ3 ’25$1.4BQ4 2025: $922.0MQ4 ’25$922.0MQ1 2026: $848.3MQ1 ’26$848.3MQ2 2026: $572.8MQ2 ’26$572.8MQ3 2026: $1.5BQ3 ’26$1.5B
Data
Q4 2024$1.1B
Q1 2025$815.8M
Q2 2025$925.4M
Q3 2025$1.4B
Q4 2025$922.0M
Q1 2026$848.3M
Q2 2026$572.8M
Q3 2026$1.5B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$3.8Bd$3.0B$3.7B$3.8B$3.9Bd$3.6B$4.3B$5.1B
Operating income$990.2Md$591.7M$1.1B$1.0B$879.9Md$642.9M$1.3B$2.0B
Operating margin26.1%19.5%29.4%27.3%22.7%17.8%30.1%40.0%
Net income$917.7Md$808.7M$1.4B$1.5B$844.6Md$727.2M$1.3B$1.9B
Diluted EPS—$7.27$12.81$13.62—$6.75$12.23$18.45
Operating cash flow$1.3Bd$1.0B$1.1Bd$1.6Bd$1.2Bd$1.1B$813.0Md$1.8Bd
Capital expenditure$199.6Md$229.3M$219.0Md$201.4Md$248.7Md$230.6M$240.2Md$300.2Md
Free cash flow$1.1B$815.8M$925.4M$1.4B$922.0M$848.3M$572.8M$1.5B
R&D expense$1.4Bd$1.3B$1.4B$1.5B$1.6Bd$1.5B$1.6B$1.8B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings